Zaragoza

• VerifyNow to Optimise Platelet Inhibition in Coronary Acute Syndrome (VERONICA) Recruiting
  2024-512436-29-00 11 2026-03-27 CARDIOVASCULAR DISEASES
• Studies testing Ziftomenib together with standard treatments in adults with newly diagnosed acute myeloid leukemia (AML) that has specific g … Recruiting
  2025-521314-25-00 5 2026-03-19 NPM1-m and KMT2A-r Acute Myeloid Leukemia
• A study to investigate the efficacy and safety of fitusiran prophylaxis in male participants aged 1 to less than 12 years with hemophilia A … Recruiting
  2025-521858-42-00 5 2026-03-16 Hemophilia
• Visugromab, nivolumab and lenvatinib compared to double placebo and lenvatinib in unresectable or metastatic hepatocellular carcinoma post a … Recruiting
  2025-520675-86-00 4 2026-03-10 Unresectable or Metastatic Hepatocellular Carcinoma and Compensated Li
• A proof of concept study to evaluate treatments´efficacy by monitoring Minimal Residual Disease using ctDNA in HR-positive/HER2-negative ear … Recruiting
  2023-505661-89-00 4 2025-12-19 Early-stage, Hormone Receptor (HR)-positive / Human Epidermal Growth F
• A Long-Term Study of the Medicine Called Abrocitinib in Children Aged 2 Years and Older with Moderate to Severe Eczema Recruiting
  2023-509124-18-00 5 2025-12-19 Moderate-to-Severe Atopic Dermatitis
• CLEOPATTRA: A research study to look at the effects of treatment with a medicine called coramitug (NNC6019-0001) in people with heart failur … Recruiting
  2024-518899-31-00 5 2025-12-19 Variant or wild-type transthyretin (TTR) amyloid cardiomyopathy
• RAGNAR: Refractory Advanced diGestive Neuroendocrine carcinomas treated with tARlatamab Recruiting
  2024-514327-42-00 4 2025-12-18 Advanced neuroendocrine carcinomas (NECs) of the digestive system or u
• Study on chemotherapy and experimental drugs in patients with Philadelphia Chromosome positive and ABL-class Philadelphia Chromosome-Like B- … Recruiting
  2025-520982-39-00 5 2025-12-09 Philadelphia Chromosome Positive or ABL-class Philadelphia Chromosome-
• A Multi-center, Double-Blind, Randomized, Two-Arm, Parallel-Group, Placebo Controlled Study to Assess the Safety of ELGN-2112 in Populations … Recruiting
  2024-517102-29-00 5 2025-11-19 Intestinal Malabsorption
• A study to assess the effect and safety of efgartigimod IV in participants from 12 years to less than 18 years of age with chronic Immune Th … Recruiting
  2025-521055-23-00 10 2025-10-07 Chronic Idiopathic thrombocytopenic purpura
• A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab vs Chemotherapy plus Pembrolizumab as First-Line Treatment o … Recruiting
  2023-508056-19-00 5 2025-10-02 HER2-Expressing (IHC 3+/IHC 2+), Mismatch Repair Proficient (pMMR), P
• A clinical study of MK-7240 for the treatment of Crohn’s disease (MK-7240-008) Recruiting
  2024-518296-56-00 5 2025-09-29 Crohn’s Disease
• Assess the safety and efficacy of sovateltide in patients with acute cerebral ischemic stroke. Recruiting
  2024-519551-29-00 5 2025-08-21 Acute cerebral ischemic stroke
• Sotorasib combined with first-line chemotherapy for advanced pancreatic adenocarcinoma Recruiting
  2024-516233-12-00 3 2025-08-08 Advanced pancreatic adenocarcinoma
• A Phase 3, Randomized, Open-Label Study of Axatilimab Versus Best Available Therapy in Participants With Chronic Graft-Versus-Host Disease A … Recruiting
  2024-518973-32-00 5 2025-07-03 Chronic Graft-Versus-Host Disease
• A PHASE 2 STUDY TO RESEARCH THE SAFETY AND EFFICACY OF TRASTUZUMAB DERUXTECAN VERSUS CDK4/6I PLUS ENDOCRINE THERAPY IN ADVANCED BREAST CANCE … Recruiting
  2024-512360-55-00 4 2025-06-30 Unresectable locally recurrent or metastatic hormone receptor (HR)-pos
• A Study to Assess Efficacy and Safety of JNJ-77242113 Compared to Placebo and Ustekinumab in Participants With Moderate to Severe Plaque Pso … Recruiting
  2024-515706-77-00 5 2025-05-08 Moderate to Severe Plaque Psoriasis
• A Study to Assess the Effectiveness and Safety of Induction Therapy with RO7790121 in Participants with Moderately to Severely Active Crohn' … Recruiting
  2024-513054-30-00 5 2025-04-16 Moderately to Severely Active Crohn's Disease (CD)
• A Randomized, Double-Blind, Placebo-Controlled, MultiRegional Phase III Clinical Study of Toripalimab Alone or in Combination With Tifcemal … Recruiting
  2023-507097-41-01 5 2025-03-20 Patients with limited-stage small cell lung cancer (LS-SCLC) without
• A Phase 3 Double-blind Study to Evaluate the Efficacy and Safety of Oral Ozanimod Compared to Oral Fingolimod in Children and Adolescents wi … Recruiting
  2022-501332-42-00 5 2025-02-26 Relapsing Remitting Multiple Sclerosis
• An Efficacy, Safety, and Tolerability Study of VRDN-003 in Participants with Active Thyroid Eye Disease (TED) Recruiting
  2024-514972-42-00 5 2025-02-25 Thyroid eye disease
• Study to provide continued access to treatment for patients completing a previous trial with efanesoctocog alfa Recruiting
  2023-506537-29-00 5 2025-02-24 Haemophilia A
• Randomized Phase 3 Trial of Quemliclustat and Chemotherapy Versus Placebo and Chemotherapy in Patients With Metastatic Pancreatic Ductal Ade … Recruiting
  2024-513317-12-00 5 2025-02-05 Pancreatic cancer

Showing 49–72 of 522 trials